Multi-modality Echocardiography for Cardiac Assessment in Primary Electrical Disease

Condition(s) studied

Investigational drug(s) / intervention(s)

Echocardiography: Multi-modality echocardiography

Study summary

From 2020 to 2023, patients with primary electrical disease (idiopathic ventricular fibrillation, long QT syndrome, Andersen-Tawil syndrome type I, Brugada syndrome, early repolarization syndrome, CPVT, and short QT syndrome) were first diagnosed at Sun Yat-sen Memorial Hospital of Sun Yat-sen University, and clinical data and echocardiographic indicators were recorded. Follow-up is until December 30, 2025 or endpoint event occurs. Endpoint events were defined as sustained ventricular tachycardia, ventricular fibrillation, sudden cardiac death, ICD discharge events, all-cause death, heart failure and heart transplantation, which were statistically analyzed as a composite endpoint of cardiovascular analysis. The predictors of primary electrical disease and the risk factors for adverse cardiovascular events were analyzed.

Eligibility

Primary outcome measure(s)

• Multi-modality echocardiography — 2 years
  tissue Doppler imging, speckle-tracking-strain, myocardial work, mechanical dispersion,electro-mechanical window

Trial sites (1)

More Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University trials in China